CRVS Company Profile and Key Details
Corvus Pharmaceuticals, Inc.
CRVS Stock Price Chart
Stock Price Today
Corvus Pharmaceuticals, Inc. (CRVS) stock declined over -5.13%, trading at $5.09 on NASDAQ, down from the previous close of $5.36. The stock opened at $5.20, fluctuating between $5.03 and $5.35 in the recent session.
Stock Snapshot
Stock Price History Chart
Contact Details
About Company
Corvus Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of immuno-oncology therapies. Its lead product candidate is Mupadolimab (CPI-006), an anti-CD73 monoclonal antibody, which is in Phase Ib/II clinical trial for non-small cell lung cancer and head and neck cancers. The company also develops CPI-818, a covalent inhibitor of ITK, which is in Phase I/Ib clinical trial to treat patients with various malignant T-cell lymphomas, as well as designed to inhibit the proliferation of certain malignant T-cells; and Ciforadenant (CPI-444), an oral, small molecule antagonist of the A2A receptor that is in Phase II clinical trial for patients with either advanced or refractory renal cell cancer. Its preclinical stage products include CPI-182, an antibody designed to block inflammation and myeloid suppression; and CPI-935, an adenosine A2B receptor antagonist to prevent fibrosis. Corvus Pharmaceuticals, Inc. has a strategic collaboration with Angel Pharmaceuticals for the development its pipeline of targeted investigational medicines. The company was incorporated in 2014 and is based in Burlingame, California.
Company Information
| Employees | 28 |
| Beta | 1.04 |
| Sales or Revenue | $0.00 |
| 5Y Sales Change% | 0% |
| Fiscal Year Ends | December |
| Sector | Healthcare |
| Industry | Biotechnology |
Frequently Asked Questions
Corvus Pharmaceuticals, Inc. (NASDAQ: CRVS) stock price is $5.09 in the last trading session. During the trading session, CRVS stock reached the peak price of $5.35 while $5.03 was the lowest point it dropped to. The percentage change in CRVS stock occurred in the recent session was -5.13% while the dollar amount for the price change in CRVS stock was -$0.28.
The NASDAQ listed CRVS is part of Biotechnology industry that operates in the broader Healthcare sector. Corvus Pharmaceuticals, Inc. designs, manufactures, and markets smartphones, personal computers, tablets, wearables, and accessories worldwide.
Dr. Peter A. Thompson FACP, M.D.
Co-Founder & Independent Chairman
Mr. Alan C. Mendelson Esq.
Sec.
Dr. Erik J. Verner Ph.D.
Co-Founder
Dr. Richard A. Miller M.D.
Co-Founder, Pres, Chief Executive Officer & Chairman
Mr. Leiv Lea
Chief Financial Officer
Dr. William Benton Jones Ph.D.
Senior Vice President of Pharmaceutical Devel.
Dr. James T. Rosenbaum M.D.
Senior Vice President of Research
CRVS's closing price is 312.31% higher than its 52-week low of $1.30 where as its distance from 52-week high of $10.00 is -46.4%.
Number of CRVS employees currently stands at 28.
Official Website of CRVS is: https://www.corvuspharma.com
CRVS could be contacted at phone 650 900 4520 and can also be accessed through its website. CRVS operates from 863 Mitten Road, Burlingame, CA 94010, United States.
CRVS stock volume for the day was 323.78K shares. The average number of CRVS shares traded daily for last 3 months was 1.07M.
The market value of CRVS currently stands at $326.75M with its latest stock price at $5.09 and 64.26M of its shares outstanding.
Stocks Telegraph provides information and tools designed to assist investors and Wall Street players. A major goal is to offer financiers comprehensive information that will help them gain insight into investing.
© 2025 Stocks Telegraph All rights reserved.
Most stock quote data provided by financialmodelingprep.com